TCRX compared with CGEM: revenue, margins and what each company keeps, and the suppliers and customers both name

TCRXTScan Therapeutics, Inc.

Mkt capRevenueRevenue

CGEMCullinan Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

TCRXTScan Therapeutics, Inc.

CGEMCullinan Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TCRX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−0.49%—

CGEM

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±23.3%▲+1.93%×0.08

May 7 '26±28.5%▼−1.80%×0.06

= impliedTCRX realized, solidCGEM realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

Q1 FY26

±25.3%

▼−2.61%

×0.10

Jan 8 '26±15.3%▲+1.83%×0.12

TCRXTScan Therapeutics, Inc.

0.18▲+1.10%· post 0.18

Mkt cap$12.7MRevenue$1MQ2 FY26Revenue$10MFY25

CGEMCullinan Therapeutics, Inc.

11.30▲+4.65%· post 11.30

ClosedNov 6 '26

Mkt cap$727.9MRevenue—Revenue—

Compare

ClosedNov 6 '26

TCRXTScan Therapeutics, Inc.

CGEMCullinan Therapeutics, Inc.

0.18▲+1.10%post 0.18

Price

11.30▲+4.65%post 11.30

$12.7M

Mkt cap

$727.9M

Q2 FY26$1M

Revenue

—

FY25$10M

Revenue

—

TCRX0.18▲+1.10%vsCGEM11.30▲+4.65%ClosedNov 6 '26